• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Studying new antibiotics for multidrug resistant infections: are today's patients paying for unproved future benefits?

作者信息

Powers John H, Evans Scott R, Kesselheim Aaron S

机构信息

George Washington University School of Medicine, Washington, DC, USA.

Department of Biostatistics and the Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, MA, USA.

出版信息

BMJ. 2018 Feb 22;360:k587. doi: 10.1136/bmj.k587.

DOI:10.1136/bmj.k587
PMID:29472192
Abstract
摘要

相似文献

1
Studying new antibiotics for multidrug resistant infections: are today's patients paying for unproved future benefits?研究用于多重耐药感染的新型抗生素：当今的患者是否在为未经证实的未来益处买单？
BMJ. 2018 Feb 22;360:k587. doi: 10.1136/bmj.k587.
2
Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015.抗击多重耐药菌的进展？2010-2015 年美国食品药品监督管理局批准抗生素回顾。
Ann Intern Med. 2016 Sep 6;165(5):363-72. doi: 10.7326/M16-0291. Epub 2016 May 24.
3
Development of novel antibacterial drugs to combat multiple resistant organisms.开发新型抗菌药物以对抗多重耐药菌。
Langenbecks Arch Surg. 2015 Feb;400(2):153-65. doi: 10.1007/s00423-015-1280-4. Epub 2015 Feb 11.
4
Quinolones and where they fit in today's environment of multidrug-resistant bugs.喹诺酮类药物及其在当今多重耐药菌环境中的地位。
Expert Rev Clin Pharmacol. 2012 Nov;5(6):609-11. doi: 10.1586/ecp.12.61.
5
Lowering methodological standards for studies of multidrug-resistant bacteria is counterproductive.降低耐多药细菌研究的方法学标准会适得其反。
Clin Microbiol Infect. 2016 Jun;22(6):497-8. doi: 10.1016/j.cmi.2016.03.024. Epub 2016 Apr 2.
6
Current and emerging drugs for acute bacterial skin and skin structure infections: an update.治疗急性细菌性皮肤和皮肤结构感染的现有及新型药物：最新进展
Expert Opin Emerg Drugs. 2014 Sep;19(3):431-40. doi: 10.1517/14728214.2014.955015. Epub 2014 Aug 22.
7
The potential risks of expedited approval of drugs for acute bacterial infections.急性细菌感染药物加速批准的潜在风险。
JAMA Intern Med. 2014 Sep;174(9):1436-7. doi: 10.1001/jamainternmed.2014.3055.
8
Preserving the lifesaving power of antimicrobial agents.保留抗菌药物的救命功效。
JAMA. 2011 Mar 9;305(10):1027-8. doi: 10.1001/jama.2011.279. Epub 2011 Feb 22.
9
[Multidrug-resistant bacteria require new treatment options].多重耐药细菌需要新的治疗选择。
Med Monatsschr Pharm. 2015 Dec;38(12):517-21.
10
[Old and new antibiotics for therapy of multidrug resistant bacteria].[用于治疗多重耐药菌的新旧抗生素]
Rev Esp Quimioter. 2016 Sep;29 Suppl 1:39-42.

引用本文的文献

1
Why too much biomedical research is often undeserving of the public's trust.为何太多的生物医学研究往往辜负公众的信任。
Front Genet. 2025 Jun 26;16:1587616. doi: 10.3389/fgene.2025.1587616. eCollection 2025.
2
Reserve antibiotics: overcoming limitations of evidence generated from regulatory approval trials.储备抗生素：克服监管批准试验所产生证据的局限性
Global Health. 2025 Apr 3;21(1):17. doi: 10.1186/s12992-025-01109-4.
3
Dynamic PK/PD Infection Models for the Development and Optimisation of Antimicrobial Regimens: A Narrative Review.
用于抗菌治疗方案开发与优化的动态药代动力学/药效学感染模型：叙述性综述
Antibiotics (Basel). 2024 Dec 10;13(12):1201. doi: 10.3390/antibiotics13121201.
4
Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant and .美罗培南-巴坦治疗革兰氏阴性菌感染（包括耐碳青霉烯菌感染）的真实世界多中心经验
Open Forum Infect Dis. 2021 Jul 14;8(8):ofab371. doi: 10.1093/ofid/ofab371. eCollection 2021 Aug.
5
Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999-2018.1999-2018 年获准上市的特定于上市前试验排除人群使用的抗生素。
Mayo Clin Proc. 2020 Dec;95(12):2699-2703. doi: 10.1016/j.mayocp.2020.07.023.
6
Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.头孢他啶阿维巴坦治疗多重耐药革兰阴性菌感染的真实世界经验
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02291-19.
7
Designing development programs for non-traditional antibacterial agents.设计非传统抗菌药物的开发项目。
Nat Commun. 2019 Jul 31;10(1):3416. doi: 10.1038/s41467-019-11303-9.
8
Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net.优化针对多药耐药菌的抗菌药物临床试验的设计和分析：COMBACTE 的 STAT-Net 的白皮书。
Clin Infect Dis. 2018 Nov 28;67(12):1922-1931. doi: 10.1093/cid/ciy516.